Does This Biotechs Failure Cast A Pall Over Its Other Prospects?

▤ Summary

"It seems difficult to conclude and we see the upcoming regulatory interactions as an even more important event," she said in a note to clients.In the results unveiled Friday, UX007 failed to significantly reduce abnormal movements associated with the disorder.The rare-disease drug also failed to meet other goals, though safety appeared consistent with earlier tests.Piper Jaffray analyst Christopher Raymond noted an earlier study showed UX007 reduced abnormal movements in another group of patients by 90%.The biggest question, Raymond James Chico said, is whether this impacts another study of UX007 in treating a recessive condition known as long-chain fatty acid oxidation disorders , or LC-FAOD.

▦ Linked Companies